International Clinical Trial: Faecalibacterium-Derived Butyrate: Modulating PMN-MDSC Immunosuppressive Phenotype and Its Impact on Sjogren's syndrome

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600135099) titled 'Faecalibacterium-Derived Butyrate: Modulating PMN-MDSC Immunosuppressive Phenotype and Its Impact on Sjogren's syndrome' on Oct. 25.

Study Type: Observational study

Study Design: Case-Control study

Primary Sponsor: The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology

Condition: Sjogren's syndrome

Intervention: Sjogren's syndrome disease group:None

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-10-29

Target Sample Size: Sjogren's syndrome disease group:30;healthy control group:30;

Countries of Recruitment: Ch...